BRIVALYST

Brivalyst is a biotechnology company dedicated to pioneering the discovery of bivalent ligands for induced proximity therapeutics. The company utilizes a proprietary platform to systematically identify and optimize bifunctional small molecules that can recruit cellular machinery, such as E3 ligases, to degrade or modify disease-causing proteins. Founded by leaders in the field of chemical biology and targeted protein degradation, Brivalyst aims to address high-value targets that have remained elusive to traditional drug discovery methods. Its platform integrates high-throughput chemical screening with advanced computational modeling to accelerate the development of potent and selective therapeutic candidates. The company's current research efforts are primarily focused on developing transformative treatments for oncology and inflammatory conditions.